查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1581204

镏177 市场：按形式、给药途径、最终用户、应用分类 - 2025-2030 年全球预测

Lutetium-177 Market by Form (Carrier Added Lutetium-177, Non-Carrier-Added Lutetium-177), Route of Administration (Intravenous, Oral), End User, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年镏177市值为1.677亿美元，预计2024年将达到2.0256亿美元，复合年增长率为21.44%，到2030年将达到6.5353亿美元。

镏-177 是一种放射性同位素，主要用于治疗神经内分泌肿瘤和某些摄护腺癌。对镏177 的需求源于其能够提供靶向辐射，同时对周围健康组织的损害最小，从而在肿瘤学中提供治疗益处。其应用包括专门从事癌症治疗的医疗中心、放射性药物製造商以及探索先进癌症治疗的研究机构。主要最终用途是医院、专科诊所和诊断中心。影响镏-177市场的主要成长要素包括癌症发生率上升、放射性药物技术的进步以及政府对癌症研究的资助增加。最近的创新重点是优化镏-177的生产和提高联合治疗中输送系统的有效性，为相关人员提供有利的机会。企业应透过投资研究合作、扩大生产设施以及寻求监管部门核准来开拓开拓的市场来抓住机会。

主要市场统计
基准年[2023] 1.677 亿美元
预测年份 [2024] 20256万美元
预测年份 [2030] 65353万美元
复合年增长率（%） 21.44%

然而，镏177 市场面临製造成本高、监管要求严格以及製造过程必需的原材料供应有限等挑战。此外，放射性药物的处理和管理需要专门的基础设施和技术人员，这限制了其广泛使用。为了克服这些障碍，技术创新可以专注于透过新颖的合成技术来提高生产效率，并加强供应链机制以确保原材料的可用性。潜在的研究领域包括开发下一代放射性标记化合物和探索针对患者特异性治疗的个人化医学方法。

该市场的特点是技术快速进步和竞争动态，需要持续的策略创新才能保持竞争力。该市场为与学术研究机构建立伙伴关係以促进产品开发和创新提供了肥沃的土壤。透过利用这些见解，市场相关人员可以驾驭监管环境，采用新技术，并优先考虑生产的永续性，以确保在不断发展的癌症药物领域占据长期地位，确保成功和市场领导地位。

市场动态：揭示快速发展的镏177 市场的关键市场洞察

供需的动态交互作用正在改变镏177 市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 在癌症治疗中越来越多地采用标靶核素治疗
    • 由于神经内分泌肿瘤盛行率不断增加，需要先进的治疗
  • 市场限制因素
    • 复杂的镏生产与供应链物流- 177
  • 市场机会
    • 放射性药物和成像技术的重大创新
    • 政府对核子医学研究的资助与支持
  • 市场挑战
    • 镏-177 监管和合规障碍及可用性限制

波特五力战略工具驾驭镏177 市场

波特五力架构是了解镏-177 市场竞争格局的关键工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解镏177 市场的外部影响

外部宏观环境因素在塑造镏177市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解镏177 市场的竞争状况

镏177 市场的详细市场占有率分析可以对供应商的业绩进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，以应对日益激烈的竞争。

FPNV 定位矩阵镏177 市场供应商绩效评估

FPNV定位矩阵是评估镏177市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划镏177 市场的成功之路

对于想要加强在全球市场的影响力的公司来说，对镏177 市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 在癌症治疗中越来越多地采用标靶放射性核素疗法
      • 神经内分泌肿瘤盛行率的增加需要先进的治疗方法
    • 抑制因素
      • 复杂的镏生产与供应链物流- 177
    • 机会
      • 放射性药物和影像技术的重大创新
      • 政府对核子医学研究的资助与支持
    • 任务
      • 镏-177 监管和合规障碍限制了可用性
  • 市场区隔分析
    • 形式：扩大使用非载体添加的镏177，由于其高纯度，最大限度地减少副作用
    • 应用：镏-177在癌症治疗中的使用正在迅速增加，提供更强化的治疗效果
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第 6 章镏177 市场：依形式

  • 运营商添加镏- 177
  • 未添加载体镏177

第 7 章镏177 市场：按管理途径

  • 静脉
  • 口服

第 8 章镏177 市场：依最终用户分类

  • 诊断中心
  • 医院
  • 专业癌症治疗中心

第 9 章镏177 市场：依应用分类

  • 癌症治疗
    • 神经内分泌肿瘤
    • 摄护腺癌
  • 非癌症治疗

第10章镏177美洲市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章 亚太地区镏177市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第12章镏177欧洲、中东和非洲市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • SHINE Technologies 与 Blue Earth Therapeutics 合作治疗摄护腺癌
    • Nuclearelectrica 和法马通合作开发镏-177 用于标靶癌症治疗，
    • Nucleus Radiopharma 与 SHINE Technologies 签署高纯度镏-177 协议，以推进癌症治疗
    • SHINE Technologies 在北美开设 Lu-177 生产设施，大幅提升癌症治疗能力
  • 战略分析和建议

公司名单

  • Actinium Pharmaceuticals, Inc.
  • Bayer AG
  • BWX Technologies, Inc.
  • Cardinal Health, Inc.
  • Curium Pharma
  • Eckert & Ziegler Radiopharma GmbH
  • Framatome
  • Fusion Pharmaceuticals Inc. by AstraZeneca
  • IBA Radiopharma Solutions
  • Isotopia Ltd.
  • ITM Isotope Technologies Munich SE
  • Lantheus Holdings, Inc.
  • NorthStar Medical Radioisotopes, LLC
  • Novartis AG
  • NTP Radioisotopes SOC Ltd.
  • Nuclear Research and Consultancy Group
  • PerkinElmer, Inc.
  • RadioMedix, Inc.
  • RayzeBio, Inc. by Bristol Myers Squibb
  • SHINE Technologies, LLC
  • Telix Pharmaceuticals Limited.
Product Code: MRR-9A6A6F2977DA

The Lutetium-177 Market was valued at USD 167.70 million in 2023, expected to reach USD 202.56 million in 2024, and is projected to grow at a CAGR of 21.44%, to USD 653.53 million by 2030.

Lutetium-177 is a radioisotope utilized primarily in targeted radionuclide therapy, notably in treating neuroendocrine tumors and certain prostate cancers. The necessity of Lutetium-177 arises from its ability to deliver targeted radiation with minimal damage to surrounding healthy tissues, offering a therapeutic advantage in oncology. Its application scopes cover medical centers specializing in oncology treatments, radiopharmaceutical manufacturers, and research institutions exploring advanced cancer therapies. The end-use predominantly spans hospitals, specialty clinics, and diagnostic centers. Key growth factors influencing the Lutetium-177 market include rising cancer prevalence, advancements in radiopharmaceutical technologies, and increased government funding for cancer research. Recent innovations focus on optimizing Lutetium-177 production and enhancing the efficacy of delivery systems in combination therapies, offering lucrative opportunities for stakeholders. Companies should seize opportunities by investing in research collaborations, expanding production facilities, and seeking regulatory approvals to harness untapped markets.

KEY MARKET STATISTICS
Base Year [2023] USD 167.70 million
Estimated Year [2024] USD 202.56 million
Forecast Year [2030] USD 653.53 million
CAGR (%) 21.44%

However, the Lutetium-177 market faces challenges such as high production costs, stringent regulatory requirements, and limited availability of raw materials elemental to the production process. Furthermore, the necessity for specialized infrastructure and skilled personnel for handling and administering radiopharmaceuticals limits widespread adoption. To overcome these barriers, innovation can focus on improving production efficiency through novel synthesis techniques and enhancing supply chain mechanisms to ensure material availability. Potential research areas include developing next-generation radiolabeled compounds and exploring personalized medicine approaches to patient-specific therapies.

The market is characterized by rapid technological advancements and competitive dynamics, requiring continuous strategic innovation to maintain a competitive edge. It presents a fertile ground for developing partnerships with academic and research institutions to fuel product development and innovation. In leveraging these insights, market players should navigate the regulatory landscape adeptly, adopt emerging technologies, and prioritize sustainability in production to ensure long-term success and market leadership in the evolving landscape of cancer therapeutics.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Lutetium-177 Market

The Lutetium-177 Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing adoption of targeted radionuclide therapy for cancer treatment
    • Rising prevalence of neuroendocrine tumors necessitates advanced therapies
  • Market Restraints
    • Complex production and supply chain logistics of lutetium-177
  • Market Opportunities
    • Significant innovations in radiopharmaceuticals and imaging technologies
    • Government funding and support for nuclear medicine research
  • Market Challenges
    • Limited availability with regulatory and compliance barriers for lutetium-177

Porter's Five Forces: A Strategic Tool for Navigating the Lutetium-177 Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Lutetium-177 Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Lutetium-177 Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Lutetium-177 Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Lutetium-177 Market

A detailed market share analysis in the Lutetium-177 Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Lutetium-177 Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Lutetium-177 Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Lutetium-177 Market

A strategic analysis of the Lutetium-177 Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Lutetium-177 Market, highlighting leading vendors and their innovative profiles. These include Actinium Pharmaceuticals, Inc., Bayer AG, BWX Technologies, Inc., Cardinal Health, Inc., Curium Pharma, Eckert & Ziegler Radiopharma GmbH, Framatome, Fusion Pharmaceuticals Inc. by AstraZeneca, IBA Radiopharma Solutions, Isotopia Ltd., ITM Isotope Technologies Munich SE, Lantheus Holdings, Inc., NorthStar Medical Radioisotopes, LLC, Novartis AG, NTP Radioisotopes SOC Ltd., Nuclear Research and Consultancy Group, PerkinElmer, Inc., RadioMedix, Inc., RayzeBio, Inc. by Bristol Myers Squibb, SHINE Technologies, LLC, and Telix Pharmaceuticals Limited..

Market Segmentation & Coverage

This research report categorizes the Lutetium-177 Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Form, market is studied across Carrier Added Lutetium-177 and Non-Carrier-Added Lutetium-177.
  • Based on Route of Administration, market is studied across Intravenous and Oral.
  • Based on End User, market is studied across Diagnostic Centers, Hospitals, and Specialized Cancer Treatment Centers.
  • Based on Application, market is studied across Cancer Treatment and Non-Cancer Treatment. The Cancer Treatment is further studied across Neuroendocrine Tumors and Prostate Cancer.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing adoption of targeted radionuclide therapy for cancer treatment
      • 5.1.1.2. Rising prevalence of neuroendocrine tumors necessitates advanced therapies
    • 5.1.2. Restraints
      • 5.1.2.1. Complex production and supply chain logistics of lutetium-177
    • 5.1.3. Opportunities
      • 5.1.3.1. Significant innovations in radiopharmaceuticals and imaging technologies
      • 5.1.3.2. Government funding and support for nuclear medicine research
    • 5.1.4. Challenges
      • 5.1.4.1. Limited availability with regulatory and compliance barriers for lutetium-177
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Form: Proliferating usage of the non-carrier-added lutetium-177 minimizing side effects due to its high purity
    • 5.2.2. Application: Burgeoning utilization of lutetium-177 in cancer treatment provides more focused therapeutic impact
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Lutetium-177 Market, by Form

  • 6.1. Introduction
  • 6.2. Carrier Added Lutetium-177
  • 6.3. Non-Carrier-Added Lutetium-177

7. Lutetium-177 Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Intravenous
  • 7.3. Oral

8. Lutetium-177 Market, by End User

  • 8.1. Introduction
  • 8.2. Diagnostic Centers
  • 8.3. Hospitals
  • 8.4. Specialized Cancer Treatment Centers

9. Lutetium-177 Market, by Application

  • 9.1. Introduction
  • 9.2. Cancer Treatment
    • 9.2.1. Neuroendocrine Tumors
    • 9.2.2. Prostate Cancer
  • 9.3. Non-Cancer Treatment

10. Americas Lutetium-177 Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Lutetium-177 Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Lutetium-177 Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. SHINE Technologies partners with Blue Earth Therapeutics for prostate cancer
    • 13.3.2. Nuclearelectrica and Framatome partnered to produce Lutetium-177 for targeted cancer treatments,
    • 13.3.3. Nucleus Radiopharma and SHINE Technologies deal for high-purity Lutetium-177 to boost cancer treatment
    • 13.3.4. SHINE Technologies opens Lu-177 production facility in North America, significantly boosting capacity for cancer treatments
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Actinium Pharmaceuticals, Inc.
  • 2. Bayer AG
  • 3. BWX Technologies, Inc.
  • 4. Cardinal Health, Inc.
  • 5. Curium Pharma
  • 6. Eckert & Ziegler Radiopharma GmbH
  • 7. Framatome
  • 8. Fusion Pharmaceuticals Inc. by AstraZeneca
  • 9. IBA Radiopharma Solutions
  • 10. Isotopia Ltd.
  • 11. ITM Isotope Technologies Munich SE
  • 12. Lantheus Holdings, Inc.
  • 13. NorthStar Medical Radioisotopes, LLC
  • 14. Novartis AG
  • 15. NTP Radioisotopes SOC Ltd.
  • 16. Nuclear Research and Consultancy Group
  • 17. PerkinElmer, Inc.
  • 18. RadioMedix, Inc.
  • 19. RayzeBio, Inc. by Bristol Myers Squibb
  • 20. SHINE Technologies, LLC
  • 21. Telix Pharmaceuticals Limited.

LIST OF FIGURES

  • FIGURE 1. LUTETIUM-177 MARKET RESEARCH PROCESS
  • FIGURE 2. LUTETIUM-177 MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL LUTETIUM-177 MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL LUTETIUM-177 MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL LUTETIUM-177 MARKET SIZE, BY FORM, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL LUTETIUM-177 MARKET SIZE, BY FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL LUTETIUM-177 MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL LUTETIUM-177 MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES LUTETIUM-177 MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES LUTETIUM-177 MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. LUTETIUM-177 MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. LUTETIUM-177 MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. LUTETIUM-177 MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL LUTETIUM-177 MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL LUTETIUM-177 MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. LUTETIUM-177 MARKET DYNAMICS
  • TABLE 7. GLOBAL LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL LUTETIUM-177 MARKET SIZE, BY CARRIER ADDED LUTETIUM-177, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL LUTETIUM-177 MARKET SIZE, BY NON-CARRIER-ADDED LUTETIUM-177, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL LUTETIUM-177 MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL LUTETIUM-177 MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL LUTETIUM-177 MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL LUTETIUM-177 MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL LUTETIUM-177 MARKET SIZE, BY SPECIALIZED CANCER TREATMENT CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL LUTETIUM-177 MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL LUTETIUM-177 MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL LUTETIUM-177 MARKET SIZE, BY NON-CANCER TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES LUTETIUM-177 MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 67. CHINA LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 71. INDIA LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 72. INDIA LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 76. INDONESIA LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 77. INDONESIA LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 81. JAPAN LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 82. JAPAN LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 86. MALAYSIA LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 87. MALAYSIA LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. MALAYSIA LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 91. PHILIPPINES LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 92. PHILIPPINES LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. PHILIPPINES LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 96. SINGAPORE LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 97. SINGAPORE LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. SINGAPORE LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 101. SOUTH KOREA LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 102. SOUTH KOREA LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. SOUTH KOREA LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 106. TAIWAN LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 107. TAIWAN LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. TAIWAN LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 111. THAILAND LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 112. THAILAND LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. THAILAND LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 116. VIETNAM LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 117. VIETNAM LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. VIETNAM LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 127. DENMARK LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 128. DENMARK LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. DENMARK LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 132. EGYPT LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 133. EGYPT LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. EGYPT LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 137. FINLAND LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 138. FINLAND LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. FINLAND LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 142. FRANCE LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 143. FRANCE LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. FRANCE LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 147. GERMANY LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 148. GERMANY LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. GERMANY LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 152. ISRAEL LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 153. ISRAEL LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 154. ISRAEL LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 157. ITALY LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 158. ITALY LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. ITALY LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 162. NETHERLANDS LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 163. NETHERLANDS LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. NETHERLANDS LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 167. NIGERIA LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 168. NIGERIA LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. NIGERIA LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 172. NORWAY LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 173. NORWAY LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 174. NORWAY LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 177. POLAND LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 178. POLAND LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. POLAND LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 182. QATAR LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 183. QATAR LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. QATAR LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 187. RUSSIA LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 188. RUSSIA LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 189. RUSSIA LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 192. SAUDI ARABIA LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 193. SAUDI ARABIA LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 194. SAUDI ARABIA LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 197. SOUTH AFRICA LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 198. SOUTH AFRICA LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH AFRICA LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 202. SPAIN LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 203. SPAIN LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 204. SPAIN LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 207. SWEDEN LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 208. SWEDEN LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 209. SWEDEN LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 212. SWITZERLAND LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 213. SWITZERLAND LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 214. SWITZERLAND LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 217. TURKEY LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 218. TURKEY LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 219. TURKEY LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 222. UNITED ARAB EMIRATES LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 223. UNITED ARAB EMIRATES LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 224. UNITED ARAB EMIRATES LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED KINGDOM LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED KINGDOM LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 232. LUTETIUM-177 MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 233. LUTETIUM-177 MARKET, FPNV POSITIONING MATRIX, 2023